Restricted accessResearch articleFirst published online 2020-8
Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials
The effect of therapeutic lowering of apolipoprotein B (apoB) on mortality and major adverse cardiovascular events is uncertain. It is also unclear whether these potential effects vary by different lipid-lowering strategies.
Methods
A total of 29 randomized controlled trials were selected using PubMed, Cochrane Library and EMBASE through 2018. We selected trials of therapies which ultimately clear apolipoprotein B particles by upregulating low-density lipoprotein receptor (LDL-R) expression (statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, bile acid sequestrants) or therapies which reduce apolipoprotein B independent of LDL-R (cholesteryl ester transfer protein inhibitor, fibrates, niacin, omega-3 fatty acids) with sample size of ≥1000 patients and follow-up of ≥1 year. The meta-regression and meta-analyses were constructed using a random effects model.
Results
In 332,912 patients, meta-regression analyses showed relative risks of 0.95 for all-cause mortality (95% confidence interval 0.92–0.99) and 0.93 (0.88–0.98) for cardiovascular mortality for every 10 mg/dL decrease in apolipoprotein B by all interventions combined. Reduction in all-cause mortality was limited to statins (0.92 (0.86–0.98)). For MACE, the relative risk per 10 mg/dL reduction in apolipoprotein B was 0.93 (0.90–0.97) for all therapies combined, with both statin (0.88 (0.83–0.93)) and non-statin therapies (0.96 (0.94–0.99)). which clear apolipoprotein B by upregulating LDL-R showing significant reductions; whereas interventions which lower apolipoprotein B independent of LDL-R did not demonstrate this effect (1.02 (0.81–1.30)).
Conclusion
While both statin and established non-statin therapies (PCSK9 inhibitor and ezetimibe) reduced cardiovascular risk per decrease in apolipoprotein B, interventions which reduce apolipoprotein B independently of LDL-R were not associated with cardiovascular benefit.
MunkhaugenJSverreEOtterstadJE, et al.Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients. Eur J Prev Cardiol2017; 24: 981–989.
PencinaMJD’AgostinoRBZdrojewskiT, et al.Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. Eur J Prev Cardiol2015; 22: 1321–1327.
4.
HarperCRJacobsonTA. Using apolipoprotein B to manage dyslipidemic patients: time for a change?Mayo Clin Proc2010; 85: 440–445.
5.
FerenceBAKasteleinJJPGinsbergHN, et al.Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA2017; 318: 947–956.
6.
TsimikasSFazioSFerdinandKC, et al.NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol2018; 71: 177–192.
7.
QuispeRElshazlyMBZhaoD, et al.Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. Eur J Prev Cardiol. Epub ahead of print 10 July 2019; DOI: 10.1177/2047487319862401.
8.
RidkerPMRifaiNCookNR, et al.Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA2005; 294: 326–333.
9.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73: 3168–3209.
10.
Van TulderMFurlanABombardierC, et al.Updated method guidelines for systematic reviews in the Cochrane collaboration back review group. Spine (Phila Pa 1976)2003; 28: 1290–1299.
11.
MoherDLiberatiATetzlaffJ, et al.Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. BMJ2009; 339: b2535–b2535.
12.
SilvermanMGFerenceBAImK, et al.Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA2016; 316: 1289–1297.
13.
NavareseEPRobinsonJGKowalewskiM, et al.Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: A systematic review and meta-analysis. JAMA2018; 319: 1566–1579.
14.
RobinsonJGWangSJacobsonTA. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol2012; 110: 1468–1476.
15.
BaigentCBlackwellL, et al.Cholesterol Treatment Trialists (CCT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet2010; 376: 1670–1681.
16.
ChoDSWooSKimS, et al.Estimation of plasma apolipoprotein B concentration using routinely measured lipid biochemical tests in apparently healthy Asian adults. Cardiovasc Diabetol2012; 11: 55–55.
17.
HigginsJPTAltmanDGGøtzschePC, et al.The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ2011; 343: d5928–d5928.
18.
KoskinasKCSiontisGCMPiccoloR, et al.Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: A meta-analysis of randomized trials. Eur Heart J2018; 39: 1172–1180.
19.
DerSimonianRLairdN. Meta-analysis in clinical trials. Control Clin Trials1986; 7: 177–188.
20.
HigginsJPTThompsonSGDeeksJJ, et al.Measuring inconsistency in meta-analyses. BMJ2003; 327: 557–560.
21.
BhattDLStegPGMillerM, et al.REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med2019; 380: 11–22.
22.
ViechtbauerW. Conducting meta-analyses in R with the metafor package. J Stat Softw2010; 36: 1–48.
23.
Campeau L, Knatterud GL, Domanski M, et al.; Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153–163.
24.
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
25.
DownsJRClearfieldMWeisS, et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998; 279: 1615–1622.
26.
Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357.
27.
PocockSJAssmannSEEnosLE, et al.Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med2002; 21: 2917–2930.
28.
CannonCPBraunwaldEMcCabeCH, et al.Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med2004; 350: 1495–1504.
29.
ColhounHMBetteridgeDJDurringtonPN, et al.CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet2004; 364: 685–696.
30.
PedersenTRFaergemanOKasteleinJJ, et al.High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA2005; 294: 2437–2445.
31.
LaRosaJCGrundySMWatersDD, et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med2005; 352: 1425–1435.
32.
AmarencoPBogousslavskyJCallahanA3rd, et al.High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med2006; 355: 549–559.
33.
RidkerPMDanielsonEFonsecaFA, et al.JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med2008; 359: 2195–2207.
34.
ArmitageJBowmanLWallendszusK, et al.Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet2010; 376: 1658–1669.
35.
YusufSBoschJDagenaisG, et al.HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med2016; 374: 2021–2031.
36.
RobinsonJGFarnierMKrempfM, et al.Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med2015; 372: 1489–1499.
37.
SabatineMSGiuglianoRPKeechAC, et al.FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med2017; 376: 1713–1722.
38.
RidkerPMRevkinJAmarencoP, et al.SPIRE Cardiovascular Outcome Investigators. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med2017; 376: 1527–1539.
39.
SchwartzGGStegPGSzarekM, et al.ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med2018; 379: 2097–2107.
40.
CannonCPBlazingMAGiuglianoRP, et al.IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med2015; 372: 2387–2397.
41.
BarterPJCaulfieldMErikssonM, et al.Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med2007; 357: 2109–2122.
42.
CannonCPShahSDanskyHM, et al.Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med2010; 363: 2406–2415.
43.
SchwartzGGOlssonAGAbtM, et al.Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med2012; 367: 2089–2099.
44.
LincoffAMNichollsSJRiesmeyerJS, et al.Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med2017; 376: 1933–1942.
45.
BowmanLHopewellJCChenF, et al.Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med2017; 377: 1217–1227.
46.
RubinsHBRobinsSJCollinsD, et al.Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med1999; 341: 410–418.
47.
KeechASimesRJBarterP, et al.Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet2005; 366: 1849–1861.
48.
AIM-HIGHInvestigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med2011; 365: 2255–2267.
49.
GroupHTCLandrayMJHaynesR, et al.Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med2014; 371: 203–212.
50.
BowmanLMafhamMWallendszusK, et al.Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med2018; 379: 1540–1550.
51.
FerenceBACannonCPLandmesserU, et al.Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: An analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur Heart J2018; 39: 2540–2545.
52.
YusufSHawkenSOunpuuS, et al.INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet2004; 364: 937–952.
53.
WalldiusGJungnerIHolmeI, et al.High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet2001; 358: 2026–2033.
54.
MoraSBuringJERidkerPM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation2014; 129: 553–561.
55.
WilkinsJTLiRCSnidermanA, et al.Discordance between apolipoprotein B and LDL-cholesterol in young adults predicts coronary artery calcification: The CARDIA Study. J Am Coll Cardiol2016; 67: 193–201.
56.
HolmesMVAla-KorpelaM. What is ‘LDL cholesterol’?Nat Rev Cardiol2019; 16: 197–198.
57.
KraussRMPintoCALiuY, et al.Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin. J Clin Lipidol2015; 9: 93–102.
58.
BilenOBallantyneCM. Bempedoic acid (ETC-1002): An investigational inhibitor of ATP citrate lyase. Curr Atheroscler Rep2016; 18: 61–61.
59.
RayKKStoekenbroekRMKallendD, et al.Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins. Circulation2018; 138: 1304–1316.
60.
XuY-XRedonVYuH, et al.Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. Atherosclerosis2018; 268: 196–206.
61.
DeweyFEGusarovaVDunbarRL, et al.Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med2017; 377: 211–221.
62.
GrahamMJLeeRGBrandtTA, et al.Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med2017; 377: 222–232.
63.
BoekholdtSMArsenaultBJMoraS, et al.Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A meta-analysis. JAMA2012; 307: 1302–1309.
64.
LangloisMRChapmanMJCobbaertC, et al.Quantifying atherogenic lipoproteins: Current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM. Clin Chem2018; 64: 1006–1033.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
